November 19, 2022:

The Big Ten Cancer Research Consortium Foundation announces that Edward M. Greenfield, PhD, has been awarded the $100,000 Kenneth and Verna Mae Jessen Award.

Dr. Greenfield is a member of the tumor microenvironment and metastasis research program at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center and professor of orthopaedic surgery at IU School of Medicine.  

September 24, 2022: 

Register now for the 2022 Big Ten CRC Summit held Saturday, November 19, 2022, in Columbus, Ohio.

We invite all senior/junior faculty and fellows involved in clinical oncology research, basic scientists involved in drug discovery and translational research, cancer center leadership and administration, community leaders and patient advocates to join us in Columbus at no cost for registration. Industry leaders and medical science liaisons are invited to the summit and to give pipeline presentations for a fee. Read More

September 13, 2022:

The University of Nebraska Medical Center, along with its partner Nebraska Medicine, will have additional resources to aggressively pursue the development and testing of new therapies for pancreatic cancer following state support that was approved earlier this year.

Read More

August 15, 2022:

The Big Ten Cancer Research Consortium (Big Ten CRC) and Cal’s Angels are pleased to announce a new collaboration to fund Adolescent/Young Adult (AYA) therapeutic cancer clinical trials conducted within the Big Ten CRC. Read More

July 13, 2022:

The Big Ten Cancer Research Consortium recently established the Kenneth and Verna Mae Jessen Award after a generous donation of $100,000 from the Verna Mae Jessen Trust. The trust supports nonprofit organizations working in cancer or pain management research. The Kenneth and Verna Mae Jessen Award will provide funding for basic, correlative, clinical, or population science oncology research. Read More

July 8, 2022: 

This month, the Big Ten Cancer Research Consortium (Big Ten CRC) highlights University of Illinois Cancer Center (UIC) as our featured member. UIC members Kent Hoskins, MD, Oana Danciu, MD and Yu “Tom” Gao, PhD, have been collaborating on BTCRC-BRE15-016, a trial identifying exosome protein biomarkers in patients with advanced hormone receptor-positive breast cancer treated with palbociclib and tamoxifen. Read More

May 20, 2022: 

Joseph Maakaron, MD of the Masonic Cancer Center at the University of Minnesota, and Kalyan Vara Ganesh Nadiminti, MBBS of the University of Wisconsin Carbone Cancer Center have been appointed as co-chairs of the Bone Marrow/Stem Cell Transplant Clinical Trial Working Group. Read More

May 11, 2022:

Seven Big Ten Cancer Research Consortium (Big Ten CRC) abstracts were highlighted during the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting held in Chicago, IL. Read More

April 20, 2022:

This month, the Big Ten Cancer Research Consortium (Big Ten CRC) highlights The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J, Solove Research Institute (OSUCCC) as our featured member. OSUCCC – James member Dwight Owen, MD, MSc is a medical oncologist and member of the Translational Therapeutics Program at the OSUCCC- James. Dr. Owen is a member of the Big Ten CRC’s correlative sciences clinical trial working group and a co-chair of the thoracic clinical trial working group. Dr. Owen shares why he is glad to be part of the Big Ten Cancer Research Consortium. Read More

April 13, 2022:

When I was recruited to Ohio State in 2009 as director of the Department of Radiation Oncology, one of our long-term goals was to extend our therapeutic reach by establishing central Ohio’s first proton therapy center in partnership with nearby Nationwide Children’s Hospital.

The center would enable both adult and pediatric patients to receive the very latest radiotherapy – namely proton therapy – in one facility that is closer to their homes, making it a less disruptive life experience. Proton therapy uses protons, or positively charged particles found within atoms, instead of X-rays to kill cancer cells. Because it more precisely targets tumor cells, it limits radiation exposure and potential damage to surrounding tissue and organs, reducing the chance of short- and long-term side effects. This is especially important for pediatric patients, whose bodies are still developing. Read More